Search

​On May 18, 2023, the Supreme Court unanimously affirmed the Federal Circuit's decision, Amgen Inc. v. Sanofi, 987 F.3d 1080 (Fed. Cir. 2021), that the claims of two of Amgen's patents were invalid for lack enablement. The involved patents, US 8,829,165 and US 8,859,741, are directed to monoclonal...

The much-anticipated Stakeholders’ call took place on April 25th. As expected, there was not a lot of detailed direction provided although it was acknowledged that to the extent questions were not answered USCIS would try to otherwise address the questions at a later point in time. The following...